Table of Contents
1 Executive Summary: India' s Pharmaceutical Sector 2008-2023
- 1.1 Prospects for India' s Pharmaceutical Market
- 1.2 Aim, Scope and Format of the Report
2 Introduction to India' s Pharmaceutical Sector
- 2.1 Historical Developments and Prospects for India' s Pharmaceutical Sector
- 2.1.1 India' s Early Years before 1970
- 2.1.2 Impetus for Increased Domestic Production 1970s
- 2.1.3 Development Phase 1980s and Growth Phase 1990s
- 2.1.4 Indian Pharmaceutical Industry Status in 2000s
- 2.3 Foreign Policy of India Related to Pharmaceutical Sector
- 2.4 India' s GDP to Grow Significantly
- 2.5 India' s Market Abroad
- 2.6 India' s Purchasing Power Parity
- 2.7 Disease Epidemiology
- 2.7.1 Malaria
- 2.7.2 TB
- 2.7.3 HIV/AIDS
- 2.7.4 Pneumonia
- 2.7.5 Diarrhoea
- 2.7.6 Cancer
- 2.7.7 Cardiovascular Diseases
- 2.7.8 Diabetes
- 2.7.9 Asthma and Bronchitis
- 2.7.10 Neurological and Psychiatric Disorders and Addictions
- 2.8 Trend in Market for Individual Therapeutic Area
3 Analysis of the Indian Pharmaceutical Market
- 3.1 Pharmaceutical Market Analysis
- 3.2 Estimated Market Value for India' s OTC Market
- 3.3 Estimated Market Value for India' s Prescription Market
- 3.4 Estimated Market Volume for India' s Generic Market
- 3.5 Branded Products Will Take Significant Market Share from 2008 to 2023
- 3.6 India' s Major Selling Medicines
- 3.7 Sales Figure for Major Therapeutics Areas
- 3.8 Forecasts for Major Therapeutics Market: Anti-Infective
- 3.9 Forecasts for Major Therapeutics Market: Other Than Anti-Infective
- 3.10 Growth Rate in India' s Therapeutic Market
4 Contract Manufacturing Businesses in India
- 4.1 Forecasts for Contract Manufacturing Services
- 4.2 Contract Manufacturing in India
- 4.2.1 Drivers for Contract Manufacturing for Outsourcing to India
- 4.3 Contract Manufacturing and Role of Indian Companies
- 4.3.1 Outsourcing for Generics
- 4.3.2 Sourcing Generics from Non-Competitors
- 4.3.3 Divi' s Laboratories' Business Model
- 4.3.4 Granules India for Production of Generic Prescription Medicines
and OTCs
- 4.3.5 Matrix Contract Manufacturer for CNS Products
- 4.3.6 Neuland Focused on Anti-Bacterials
- 4.3.7 Natco Chose Chronic Diseases
- 4.4 Enforcing GMP Compliance for APIs in EU
- 4.5 Growth in Biotechnology Sector of India
- 4.5.1 Ranbaxy' s Entry Into Biotechnology
5 Contract Research Businesses in India
- 5.1 Forecasts for Contract Research
- 5.2 Focus on Innovative R&D
- 5.3 CROs to Maintain High Quality
- 5.4 Drivers and Restrains for Outsourcing Clinical Research Services from
India
- 5.5 Contract Research and Companies
- 5.5.1 R&D Investments by Foreign MNCs in India
- 5.5.2 Vimta is an Emerging Company
- 5.5.3 Suven is Emerging as a Contract R&D Focused
- 5.5.4 Wellquest is a CRO Compliant with International Regulatory Norms
- 5.6 Outsourcing Clinical Data Management
- 5.6.1 GlaxoSmithKline to Outsource Data Management
- 5.6.2 Clininvent is a CRO with Standardised Data Management Skills
- 5.7 Emerging Outsourcing Models
- 5.8 National Drug Authority to be Formed
- 5.9 Firsthand Interview for Expert Opinion on Clinical Research 1
- 5.9.1 Small and Medium Sized Companies Opt For CROs
- 5.9.2 Pros and Cons of Contract Research Services from India
- 5.9.3 India' s Own Innovative Products
- 5.9.4 Differences between India and China for Undertaking Trials
- 5.10 Firsthand Interview for Expert Opinion on Clinical Research 2
- 5.10.1 Asian Nations with Proven Efficacy to Undertake Clinical Trials
- 5.11 Firsthand Interview for Expert Opinion on Clinical Research 3
- 5.11.1 Pros and Cons of Contract Research Services from India
6 India' s Pharmaceutical Company Profile and Opportunities with Them
- 6.1 Suitable Business Models for Individual Pharmaceutical Companies in
India
- 6.1.1 Merger and Acquisition (M&A) for Indian Companies
- 6.1.1.1 Dr Reddy Acquires Betapharm
- 6.1.2 Indian Pharmaceutical Companies Enter World Market
- 6.1.2.1 Zyday Cadila
- 6.1.2.2 Sun
- 6.1.2.3 Alkem
- 6.1.2.4 Wockhardt
- 6.1.2.5 Lupin
- 6.1.2.6 Ranbaxy
- 6.1.2.7 Cipla
- 6.1.3 Collaboration for Expansion and Improvement
- 6.1.4 Good Manufacturing Practice (GMP) Compliance
- 6.1.5 Foreign MNCs Maintain Significant Market Share in India
- 6.1.5.1 GlaxoSmithKline' s Significant Market Share in India
- 6.1.5.2 Pfizer Emerged as the Most Significant Pharmaceutical Patent
Applicant in India
7 SWOT Analysis for India' s Pharmaceutical Market
- 7.1 The Existing Advantages of India' s Pharmaceutical Sector
- 7.2 Vision for India' s Pharmaceutical Sector
- 7.3 Goal of India' s Pharmaceutical Sector
- 7.4 Visiongain Suggests Following Strategies for India' s Pharmaceutical
Sector
- 7.5 Drivers and Restrain for India' s Pharmaceutical Sector
- 7.6 India' s Changing Demographic Profile
- 7.6.1 Public Healthcare System
- 7.6.2 Private Sector Contribution to Healthcare
- 7.6.3 Uneven Distribution of Healthcare
- 7.7 India' s Pricing Pattern for Pharmaceutical Industry
- 7.7.1 Private Spending for Healthcare
- 7.7.2 Wholesale Distribution and Price Regulation
- 7.8 Firsthand Interview for Expert Opinion 1
- 7.8.1 Bureaucracy as Obstacles
- 7.8.2 Improving Access to Rural Areas
- 7.8.3 Therapeutic Areas to Get Increased Attention from 2008 to 2023
- 7.8.4 Drug Resistance for Antibiotics as Unmet Needs
- 7.9 Firsthand Interview for Expert Opinion 2
- 7.9.1 India' s Key Strength
- 7.9.2 India' s Edge Over China In Pharmaceutical Business
- 7.9.3 Need for Routine Inspection of Outsourcing Sites
- 7.9.4 Need for Creation of Economic Zone for Pharmaceutical Industry
- 7.9.5 Business Approach Needed for Rural Mass
- 7.9.6 India as an Emerging Market
- 7.9.7 Growth of India' s Medical Tourism
- 7.9.8 Tropical Diseases Widespread in India
- 7.9.9 Vertical Integration Recommended for India' s Companies
- 7.9.10 India' s Emergence as a Major Pharmaceutical Market
8 Conclusions
- 8.1 India' s Progress in Healthcare
- 8.2 Increases in Demand for Private Healthcare
- 8.3 Increases in Patient Demand for Service Provision
- 8.4 India' s Progress in Pharmaceuticals and Outsourcing Services
- 8.5 Recommendations for India' s Pharmaceutical Sector
- 8.6 Recommendations to Foreign Pharmaceutical Companies for India' s Market
Tables
- Table 1.1 Forecasts for India' s Pharmaceutical Industry' s Market, 2008,
2013, 2018 & 2023
- Table 3.1 Pharmaceutical Sales ($bn) of Top 20 Nations, 2006
- Table 3.2 India' s Total Pharmaceutical Sales ($m), 2008-2014
- Table 3.3 India' s Total Pharmaceutical Sales ($m), 2015-2023
- Table 3.4 Forecasts for India' s Pharmaceutical Industry' s Market, 2008,
2013, 2018 & 2023
- Table 3.5 Forecasts for India' s International OTC Market ($m), 2006-
2014
- Table 3.6 Forecasts for India' s International OTC Market ($m), 2015-2023
- Table 3.7 Forecasts for India' s Domestic OTC Market,($m), 2006-2014
- Table 3.8 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
- Table 3.9 Forecasts for India' s Prescription Market ($m), 2006-2014
- Table 3.10 Forecasts for India' s Prescription Market ($m), 2015-2023
- Table 3.11 Forecasts for Cephalosporins Sales ($m), 2006-2014
- Table 3.12 Forecasts for Cephalosporins Sales( $m), 2015-2023
- Table 3.13 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006-2014
- Table 3.14 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015-2023
- Table 3.15 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
- Table 3.16 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
- Table 3.17 Forecasts for Macrolides Sales ($m), 2006-2014
- Table 3.18 Forecasts for Macrolides Sales ($m), 2015-2023
- Table 3.19 Forecasts for Anti-Malarial Sales ($m), 2006-2014
- Table 3.20 Forecasts for Anti-Malarial Sales($m), 2015-2023
- Table 3.21 Forecasts for Anti-TB Sales ($m), 2006-2014
- Table 3.22 Forecasts for Anti-TB Sales ($m), 2015 -2023
- Table 3.23 Forecasts for Anti-Diarrhoeal Sales($m), 2006-2014
- Table 3.24 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
- Table 3.25 Forecasts for Amoebicides Sales($m), 2006-2014
- Table 3.26 Forecasts for Amoebicides Sales ($m), 2015-2023
- Table 3.27 Forecasts for NSAID Sales ($m), 2006-2014
- Table 3.28 Forecasts for NSAID Sales ($m), 2015-2023
- Table 3.29 Forecasts for H2 Receptor Blockers Sales($m), 2006-2014
- Table 3.30 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
- Table 3.31 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
- Table 3.32 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
- Table 3.33 Forecasts for Anti-Tussives Sales ($m), 2006-2014
- Table 3.34 Forecasts for Anti-Tussives Sales ($m), 2015-2023
- Table 3.35 Forecasts for Haematinics, Iron and Combination Sales ($m),
2006-2014
- Table 3.36 Forecasts for Haematinics, Iron and Combination Sales ($m),
2008-2023
- Table 3.37 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
- Table 3.38 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
- Table 3.39 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
- Table 3.40 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
- Table 3.41 Forecasts for Expectorants Sales ($m), 2006-2014
- Table 3.42 Forecasts for Expectorants Sales ($m), 2015-2023
- Table 3.43 Forecasts for Topical Corticosteroids Sales ($m), 2006-2014
- Table 3.44 Forecasts for Topical Corticosteroids Sales ($m), 2015-2023
- Table 3.45 Forecasts for Angiotensin II Antagonist (Combination) Sales
($m), 2006-2014
- Table 3.46 Forecasts for Angiotensin II Antagonist (Combination) Sales
($m), 2015-2023
- Table 3.47 Forecasts for Antacid Sales ($m), 2006-2014
- Table 3.48 Forecasts for Antacid Sales ($m), 2015 -2023
- Table 3.49 Forecasts for Calcium Sales ($m), 2006-2014
- Table 3.50 Forecasts for Calcium Sales ($m), 2015 -2023
- Table 3.51 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
- Table 3.52 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
- Table 3.53 Forecasts for Anti-Histamine Sales ($m), 2006-2014
- Table 3.54 Forecasts for Anti-Histamine Sales ($m), 2015-2023
- Table 3.55 Forecasts for Anti-Depressant Sales ($m), 2006-2014
- Table 3.56 Forecasts for Anti-Depressant Sales ($m), 2015-2023
- Table 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m),
2006-2014
- Table 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m),
2015-2023
- Table 5.1 Forecasts for India' s Contract Research Revenues ($m),
2006-2014
- Table 5.2 Forecasts for India' s Contract Research Revenues( $m),
2015-2023
- Table 5.3 Dr Reddy' s Pipeline Strength
- Table 6.1 Fastest Growing Local Companies from Top 50 in India
- Table 6.2 Leading Local Companies from Top 100 in India
- Table 6.3 Leading Corporate Groups
- Table 6.4 Merger and Acquisition Activities of Indian Companies, 2007
- Table 6.5 International M&A of Indian Firms
- Table 7.1 SWOT Analysis for India' s Pharmaceutical Sector
- Table 7.2 India' s Demographic Profile, 2007
Figures
- Figure 1.1 Forecasts for India' s Pharmaceutical Industry' s Market ($m),
2008, 2013,2018 & 2023
- Figure 2.1 Developments and Prospects for India' s Pharmaceutical Sector
(Past,Present & Future)
- Figure 2.2 India' s Pharmaceutical Industry Culture and Attributes Figure
3.1 Countries Ranked by Pharmaceutical Market Share, 2006
- Figure 3.2 Ratio of Domestic Pharmaceutical Market Share by Value with
Export,2006
- Figure 3.3 India' s Total Pharmaceutical Sales ($m), 2006-2014
- Figure 3.4 India' s Total Pharmaceutical Sales ($m), 2015-2023
- Figure 3.5 Forecasts for India' s Pharmaceutical Industry' s Market, 2008,
2013, 2018 & 2023
- Figure 3.6 Forecasts for India' s International OTC Market ($m), 2006-2014
- Figure 3.7 Forecasts for India' s International OTC Market ($m), 2015-2023
- Figure 3.8 Forecasts for India' s Domestic OTC Market ($m), 2006-2014
- Figure 3.9 Forecasts for India' s Domestic OTC Market ($m), 2015-2023
- Figure 3.10 Ratio for Domestic and International OTC Market Share ($m),
India, 2006
- Figure 3.11 Forecasts for India' s Prescription Market ($m), 2006-2014
- Figure 3.12 Forecasts for India' s Prescription Market ($m), 2015-2023
- Figure 3.13 Proportion of India' s Generic Market Share by Volume in Global
Market,2008
- Figure 3.14 Proportion of India' s Generic Market Share by Volume in Global
Market,2023
- Figure 3.15 Ratio for Patent and Generic Market Share by Value, India, 2007
- Figure 3.16 Ratio for Patent and Generic Market Share by Value, India, 2023
- Figure 3.17 Major Anti-Infective Sales ($m), India, 2006
- Figure 3.18 Major Selling Prescription Medicines Other Than Anti-Infective
($m),India, 2006
- Figure 3.19 Major Selling OTC Medicines Other Than Anti-Infective ($m),
India, 2006
- Figure 3.20 Ratio of Anti-Infective to Other Medicines in the Market,
India, 2008
- Figure 3.21 Forecasts for Cephalosporins Sales ($m), 2006-2014
- Figure 3.22 Forecasts for Cephalosporins Sales ($m), 2015-2023
- Figure 3.23 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006- 2014
- Figure 3.24 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023
- Figure 3.25 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
- Figure 3.26 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
- Figure 3.27 Forecasts for Macrolides Sales ($m), 2006-2014
- Figure 3.28 Forecasts for Macrolides Sales ($m), 2015-2023
- Figure 3.29 Forecasts for Anti-Malarial Sales ($m), 2006-2014
- Figure 3.30 Forecasts for Anti-Malarial Sales ($m), 2015-2023
- Figure 3.31 Forecasts for Anti-TB Sales ($m), 2006-2014
- Figure 3.32 Forecasts for Anti-TB Sales ($m), 2015 -2023
- Figure 3.33 Forecasts for Anti-Diarrhoeal Sales ($m), 2006-2014
- Figure 3.34 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
- Figure 3.35 Forecasts for Amoebicides Sales ($m), 2006-2014
- Figure 3.36 Forecasts for Amoebicides Sales ($m), 2015-2023
- Figure 3.37 Forecasts for NSAIDs Sales ($m), 2006-2014
- Figure 3.38 Forecasts for NSAIDs Sales ($m), 2015-2023
- Figure 3.39 Forecasts for H2 Receptor Blockers Sales ($m), 2006-2014
- Figure 3.40 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
- Figure 3.41 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
- Figure 3.42 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
- Figure 3.43 Forecasts for Anti-Tussives Sales ($m), 2006-2014
- Figure 3.44 Forecasts for Anti-Tussives Sales ($m), 2015-2023
- Figure 3.45 Forecasts for Haematinics, Iron and Combination Sales ($m),
2006-2014
- Figure 3.46 Forecasts for Haematinics, Iron and Combination Sales ($m),
2008-2023
- Figure 3.47 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
- Figure 3.48 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
- Figure 3.49 Forecasts for Multi-Vitamins and Minerals Sales ($m),
2006-2014
- Figure 3.50 Forecasts for Multi-Vitamins and Minerals Sales ($m),
2015-2023
- Figure 3.51 Forecasts for Expectorants Sales ($m), 2006-2014
- Figure 3.52 Forecasts for Expectorants Sales ($m), 2015-2023
- Figure 3.53 Forecasts for Topical Corticosteroids Sales ($m), 2006- 2014
- Figure 3.54 Forecasts for Topical Corticosteroids Sales ($m), 2015- 2023
- Figure 3.55 Forecasts for Angiotensin II Antagonist (Combination) Sales
($m), 2006-2014
- Figure 3.56 Forecasts for Angiotensin II Antagonist (Combination) Sales
($m), 2015-2023
- Figure 3.57 Forecasts for Antacid Sales ($m), 2006-2014
- Figure 3.58 Forecasts for Antacid Sales ($m), 2015 -2023
- Figure 3.59 Forecasts for Calcium Sales ($m), 2006-2014
- Figure 3.60 Forecasts for Calcium Sales ($m), 2015 -2023
- Figure 3.61 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
- Figure 3.62 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
- Figure 3.63 Forecasts for Anti-Histamine Sales ($m), 2006-2014
- Figure 3.64 Forecasts for Anti-Histamine Sales ($m), 2015-2023
- Figure 3.65 Forecasts for Anti-Depressant Sales ($m), 2006-2014
- Figure 3.66 Forecasts for Anti-Depressant Sales ($m), 2015-2023
- Figure 3.67 Growth Rate According to Therapeutic Areas ($m), 2007
- Figure 4.1 Forecasts for India' s Contract Manufacturing Revenues ($m),
2008-2014
- Figure 4.2 Forecasts for India' s Contract Manufacturing Revenues ($m),
2015-2023
- Figure 4.3 Path Up the Value Chain for Indian Companies
- Figure 5.1 Forecasts for India' s Contract Research Revenues ($m),
2008-2014
- Figure 5.2 Forecasts for India' s Contract Research Revenues ($m),
2015-2023
Organisations Mentioned in the Report:
- Actavis
- Alkem
- Allen Spa
- Agency National for Vigilance Sanitaire (ANVISA)
- Advanced Medical Optics
- AstraZeneca
- Aurobindo
- Avecia
- Aventis
- Betapharm
- B-Tabs
- Bulk Drug Manufacturers Association
- Carbogen and Amcis
- Central Drugs Standards Control Organisation (CDSCO)
- Cipla
- Clininvent
- Dishman
- Divi' s
- Docpharma
- Dr. Reddy' s
- Elder
- Eli Lilly
- Emcure
- Ethimed
- FDA
- Geneva
- GlaxoSmithKline
- Government of India
- Granules India
- Hollister-Stier
- Indian Drug Manufacturers' Association
- IMS Health
- Ind-Swift
- Intas
- International Monetary Fund
- Johnson & Johnson
- Jubilant Organosys
- Lupin
- Macleods
- Mankind
- Matrix
- Medicamenta
- Medley
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Medicines Control Council (MCC)
- Mundogen
- Mylan
- Natco
- National Institute of Pharmacy (NIP)
- Negma
- Neuland
- Nicholas Piramal
- Novartis
- Novo Nordisk
- Organisation of Pharmaceutical Producers of India (OPPI)
- Perigo
- Pfizer
- Pharmaceutical Inspection Convention (PIC)
- Pinewood
- Quintiles
- Ranbaxy
- Rexcel
- Rhodia
- Roche
- Sanmar API
- Sanofi-Aventis
- Shasun
- Solvay
- Sun
- Suven
- Taro
- Tata Consulting Services
- Terapia
- Therapeutic Goods Administration (TGA)
- Vimta
- Wellquest
- World Bank
- Wockhardt
- World Health Organisation (WHO)
- World Trade Organization (WTO)
- Zenotech
- Zuventus
- Zydus Cadila
|
Related Report
|
View Cart
